5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)???A new antitumor agent with activity against malignant melanoma, European Journal of Cancer (1965), vol.8, issue.1, pp.85-92, 1972. ,
DOI : 10.1016/0014-2964(72)90087-4
Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer, Journal of Managed Care Pharmacy, vol.13, issue.6 Supp C, pp.5-18, 2007. ,
DOI : 10.18553/jmcp.2007.13.s6-c.5
Natural products to drugs: natural product-derived compounds in clinical trials, Natural Product Reports, vol.17, issue.suppl 2, pp.475-516, 2008. ,
DOI : 10.1007/s00280-008-0720-z
Mother Nature???s gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery, Prog Drug Res, vol.65, pp.3-44, 2008. ,
DOI : 10.1007/978-3-7643-8117-2_1
Adriamycin, Annals of Internal Medicine, vol.80, issue.2, pp.249-259, 1974. ,
DOI : 10.7326/0003-4819-80-2-249
Mitomycin, a new antibiotic from Streptomyces. I, J Antibiot (Tokyo), vol.9, pp.141-146, 1956. ,
Clinical efficacy and emerging therapeutic utilization of novel taxanes, European Journal of Cancer Supplements, vol.6, issue.10, pp.12-21, 2008. ,
DOI : 10.1016/S1359-6349(08)71922-0
Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer, European Journal of Cancer Supplements, vol.6, issue.10, pp.3-11, 2008. ,
DOI : 10.1016/S1359-6349(08)71921-9
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy, Therapeutics and Clinical Risk Management, vol.1, issue.2, pp.107-114, 2005. ,
DOI : 10.2147/tcrm.1.2.107.62910
Protein nanoparticles as drug carriers in clinical medicine, Advanced Drug Delivery Reviews, vol.60, issue.8, pp.876-885, 2008. ,
DOI : 10.1016/j.addr.2007.08.044
Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects, Advanced Drug Delivery Reviews, vol.60, issue.8, pp.939-954, 2008. ,
DOI : 10.1016/j.addr.2007.11.008
Topotecan for the treatment of small-cell lung cancer, Expert Review of Anticancer Therapy, vol.7, issue.6, pp.795-801, 2007. ,
DOI : 10.1586/14737140.7.6.795
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors, Annals of Oncology, vol.12, issue.11, pp.1643-1649, 2001. ,
DOI : 10.1023/A:1013180903805
A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-smallcell lung cancer patients, Annals of Oncology, vol.12, issue.10, pp.1375-1381, 2001. ,
DOI : 10.1023/A:1012539225493
Overview of the changing paradigm in cancer treatment: Oral chemotherapy, American Journal of Health-System Pharmacy, vol.64, issue.9 Supplement 5, pp.4-7, 2007. ,
DOI : 10.2146/ajhp070035
Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC, Lung Cancer, vol.62, issue.1, 2008. ,
DOI : 10.1016/j.lungcan.2008.02.009
Effective oral chemotherapy for breast cancer: pillars of strength, Annals of Oncology, vol.19, issue.2, pp.212-222, 2008. ,
DOI : 10.1093/annonc/mdm285
Epothilones, a new class of microtubule-stabilizing agents with a taxollike mechanism of action, Cancer Res, vol.55, pp.2325-2333, 1995. ,
first in a new class of antineoplastic agents: the natural epothilones and their analogues, Clin Breast Cancer, vol.7, pp.757-763, 2007. ,
Preclinical discovery of ixabepilone, a highly active antineoplastic agent, Cancer Chemotherapy and Pharmacology, vol.25, issue.Suppl 1, 2008. ,
DOI : 10.1007/s00280-008-0724-8
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone, Cancer Chemotherapy and Pharmacology, vol.25, issue.Suppl, 2008. ,
DOI : 10.1007/s00280-008-0727-5
Epothilones as lead structures for new anticancer drugs ??? pharmacology, fermentation, and structure-activity-relationships, Prog Drug Res, vol.66, pp.275-334, 2008. ,
DOI : 10.1007/978-3-7643-8595-8_6
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743, Proceedings of the National Academy of Sciences, vol.104, issue.32, pp.13062-13067, 2007. ,
DOI : 10.1073/pnas.0609877104
Trabectedin, Drugs, vol.361, issue.9375, pp.2257-2276, 2007. ,
DOI : 10.2165/00003495-200767150-00009
Marine natural products as anticancer drugs, Mol Cancer Ther, vol.4, pp.333-342, 2005. ,
Biodiversity, chemical diversity and drug discovery, Prog Drug Res, vol.65, pp.143-174, 2008. ,
DOI : 10.1007/978-3-7643-8117-2_4
Marine pharmacology in 2005???2006: Antitumour and cytotoxic compounds, European Journal of Cancer, vol.44, issue.16, pp.2357-2387, 2005. ,
DOI : 10.1016/j.ejca.2008.07.001
Temsirolimus, Drugs of Today, vol.43, issue.10, pp.659-669, 2007. ,
DOI : 10.1358/dot.2007.43.10.1148059
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC, Nature Clinical Practice Oncology, vol.12, issue.10, 2008. ,
DOI : 10.1038/ncponc1173
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle., The Journal of Antibiotics, vol.28, issue.10, pp.721-726, 1975. ,
DOI : 10.7164/antibiotics.28.721
Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed, Clinical Pharmacology & Therapeutics, vol.431, issue.4, pp.381-388, 2007. ,
DOI : 10.1038/sj.clpt.6100317
The impact of natural products upon modern drug discovery, Current Opinion in Chemical Biology, vol.12, issue.3, pp.306-317, 2008. ,
DOI : 10.1016/j.cbpa.2008.03.016
Vinflunine: Discovery and Synthesis of a Novel Microtubule Inhibitor, Seminars in Oncology, vol.35, pp.3-5, 2008. ,
DOI : 10.1053/j.seminoncol.2008.01.004
Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors, Seminars in Oncology, vol.35, pp.34-43, 2008. ,
DOI : 10.1053/j.seminoncol.2008.01.008
Amrubicin for non-small-cell lung cancer and small-cell lung cancer, Investigational New Drugs, vol.28, issue.1, pp.499-504, 2007. ,
DOI : 10.1007/s10637-007-9069-0
The Hsp90 molecular chaperone: an open and shut case for treatment, Biochemical Journal, vol.410, issue.3, pp.439-453, 2008. ,
DOI : 10.1042/BJ20071640
Chinese herb related molecules of cancer-cell-apoptosis: a minireview of progress between Kanglaite injection and related genes, Journal of Experimental & Clinical Cancer Research, vol.27, issue.1, p.31, 2008. ,
DOI : 10.1186/1756-9966-27-31
ASIAN MEDICINE: The New Face of Traditional Chinese Medicine, Science, vol.299, issue.5604, pp.188-190, 2003. ,
DOI : 10.1126/science.299.5604.188
Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity, Molecular Cancer Therapeutics, vol.7, issue.5, pp.1285-1296, 2008. ,
DOI : 10.1158/1535-7163.MCT-07-2241
The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death, Blood, vol.111, issue.4, pp.1951-1961, 2008. ,
DOI : 10.1182/blood-2007-05-089219
Bioguided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds?, Journal of Ethnopharmacology, vol.100, issue.1-2, pp.57-60, 2005. ,
DOI : 10.1016/j.jep.2005.05.029
Plant natural products: Back to the future or into extinction?, Phytochemistry, vol.68, issue.14, pp.2015-2022, 2007. ,
DOI : 10.1016/j.phytochem.2007.04.032
Natural products from cyanobacteria: Exploiting a new source for drug discovery, IDrugs, vol.9, pp.119-127, 2006. ,
Biosynthetic origin of natural products isolated from marine microorganism-invertebrate assemblages, Proceedings of the National Academy of Sciences, vol.105, issue.12, pp.4587-4594, 2008. ,
DOI : 10.1073/pnas.0709851105
Evolving Trends in the Dereplication of Natural Product Extracts: New Methodology for Rapid, Small-Scale Investigation of Natural Product Extracts, Journal of Natural Products, vol.71, issue.9, 2008. ,
DOI : 10.1021/np8002222
High impact technologies for natural products screening, Prog Drug Res, vol.65, pp.177-210, 2008. ,
DOI : 10.1007/978-3-7643-8117-2_5
Natural products as a screening resource, Current Opinion in Chemical Biology, vol.11, issue.5, pp.480-484, 2007. ,
DOI : 10.1016/j.cbpa.2007.08.012
Histone deacetylase inhibitors from microorganisms: the Astellas experience, Prog Drug Res, vol.66, pp.335-337, 2008. ,
DOI : 10.1007/978-3-7643-8595-8_7
High-Throughput Bioluminescence Screening of Ubiquitin-Proteasome Pathway Inhibitors from Chemical and Natural Sources, Journal of Biomolecular Screening, vol.69, issue.1, pp.106-116, 2007. ,
DOI : 10.1177/1087057106296494
Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis, Biochemical Pharmacology, vol.76, issue.4, pp.453-462, 2008. ,
DOI : 10.1016/j.bcp.2008.05.031
Rapid Generation of Single-Tumor Spheroids for High-Throughput Cell Function and Toxicity Analysis, Journal of Biomolecular Screening, vol.117, issue.8, pp.922-932, 2006. ,
DOI : 10.1177/1087057106292763
Screening for Compounds That Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids, Journal of Biomolecular Screening, vol.13, issue.1, pp.1-8, 2008. ,
DOI : 10.1177/1087057107310442
Experimental anti-tumor therapy in 3-D: Spheroids ??? old hat or new challenge?, International Journal of Radiation Biology, vol.10, issue.11-12, pp.849-871, 2007. ,
DOI : 10.1007/s10456-004-8911-7
A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine, British Journal of Pharmacology, vol.4, issue.3, pp.321-334, 2007. ,
DOI : 10.1038/sj.bjp.0706988
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade, Clinical Cancer Research, vol.14, issue.6, pp.1649-57, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-2218
Bortezomib in the Treatment of Cancer, Recent Patents on Anti-Cancer Drug Discovery, vol.1, issue.3, pp.397-403, 2006. ,
DOI : 10.2174/157489206778776925
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma, Blood, vol.111, issue.3, pp.1654-1664, 2008. ,
DOI : 10.1182/blood-2007-08-105601
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma, Blood, vol.110, issue.9, pp.3281-3290, 2007. ,
DOI : 10.1182/blood-2007-01-065888
Advances in and applications of proteasome inhibitors, Current Opinion in Chemical Biology, vol.12, issue.4, pp.434-440, 2008. ,
DOI : 10.1016/j.cbpa.2008.06.033
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism, Nature, vol.59, issue.7188, pp.755-758, 2008. ,
DOI : 10.1038/nature06782
Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis, Cell Proliferation, vol.154, issue.6, pp.599-609, 2006. ,
DOI : 10.1074/jbc.M204962200
Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer, Journal of Medicinal Chemistry, vol.51, issue.4, pp.1068-1072, 2008. ,
DOI : 10.1021/jm7010589
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib, Blood, vol.111, issue.5, pp.2765-2775, 2008. ,
DOI : 10.1182/blood-2007-07-100651
The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases, Cardiovascular & Hematological Disorders-Drug Targets, vol.7, issue.4, pp.250-273, 2007. ,
DOI : 10.2174/187152907782793572
Proteasome inhibition as a novel therapy in treating rheumatoid arthritis, Medical Hypotheses, vol.71, issue.1, pp.65-72, 2008. ,
DOI : 10.1016/j.mehy.2008.02.014
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies, Biochemical Pharmacology, vol.75, issue.6, pp.1262-1271, 2008. ,
DOI : 10.1016/j.bcp.2007.10.016
Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I, Nature, vol.381, issue.6577, pp.80-82, 1996. ,
DOI : 10.1038/381080a0
RRM Proteins Interacting with the Cap Region of Topoisomerase I, Journal of Molecular Biology, vol.369, issue.4, pp.1098-1112, 2007. ,
DOI : 10.1016/j.jmb.2007.04.017
Specific inhibition of serine-and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506, Cancer Res, vol.61, pp.6876-6884, 2001. ,
The Splicing Factor SF2/ASF Regulates Translation Initiation by Enhancing Phosphorylation of 4E-BP1, Molecular Cell, vol.30, issue.2, pp.179-189, 2008. ,
DOI : 10.1016/j.molcel.2008.03.013
Reversible phosphorylation differentially affects nuclear and cytoplasmic functions of splicing factor 2/alternative splicing factor, Proceedings of the National Academy of Sciences, vol.102, issue.42, pp.15042-15047, 2005. ,
DOI : 10.1073/pnas.0507827102
The gene encoding the splicing factor SF2/ASF is a proto-oncogene, Nature Structural & Molecular Biology, vol.66, issue.3, pp.185-193, 2007. ,
DOI : 10.1038/sj.onc.1202835
Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks, Journal of Biological Chemistry, vol.279, issue.23, pp.24246-24254, 2004. ,
DOI : 10.1074/jbc.M314298200
SR Proteins as Potential Targets for Therapy, Prog Mol Subcell Biol, vol.44, pp.65-87, 2006. ,
DOI : 10.1007/978-3-540-34449-0_4
Novel cytotoxic drugs: Old challenges, new solutions, Cancer Treatment Reviews, vol.34, issue.1, pp.81-91, 2008. ,
DOI : 10.1016/j.ctrv.2007.08.001
Development trends for new cancer therapeutics and vaccines, Drug Discovery Today, vol.13, issue.1-2, pp.30-37, 2008. ,
DOI : 10.1016/j.drudis.2007.09.003